STREPTOMYCIN AND PYRIDOMYCIN DRUG MOLECULES PROVIDE THE MOST POTENTIAL INHIBITORS AGAINST RV3871 TO CURE TUBERCULOSIS

نویسندگان

چکیده

The ESX-1 secretion system of Mycobacterium tuberculosis delivers bacterial virulence factors to host cells during infection. most abundant factor, the ESAT-6/CFP-10 dimer, is targeted for via a C-terminal signal sequence on CFP-10 that recognized by cytosolic ATPase, Rv3871. ATPase component system. ESX locus contains genes encoding conserved machinery components termed EccCb1. these core are required [70, 71]. Rv3871 cytoplasmic protein connected with Rv3870 and encoded EccCb1 gene. These proteins supply energy process. Each ATPases involved in targeting secretion. binds seven amino acid peptide CFT- 10, which complex. In this we target c-terminal region block it through multiple drugs so, cannot be activated not infection (Tuberculosis). present study have comparatively studied different inhibitory antagonist drug molecule could potential inhibit responsible supply. We 16 antagonistic molecules as shortlisted based previous studies, site molecule. KEYWORDS: Tuberculosis/Drug target/Molecular Docking/Screening antituberculosis drug.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Towards a new tuberculosis drug: pyridomycin – nature's isoniazid

Tuberculosis, a global threat to public health, is becoming untreatable due to widespread drug resistance to frontline drugs such as the InhA-inhibitor isoniazid. Historically, by inhibiting highly vulnerable targets, natural products have been an important source of antibiotics including potent anti-tuberculosis agents. Here, we describe pyridomycin, a compound produced by Dactylosporangium fu...

متن کامل

Designing of inhibitors against drug tolerant Mycobacterium tuberculosis (H37Rv)

BACKGROUND Mycobacterium tuberculosis (M.tb) is the causative agent of tuberculosis, killing ~1.7 million people annually. The remarkable capacity of this pathogen to escape the host immune system for decades and then to cause active tuberculosis disease, makes M.tb a successful pathogen. Currently available anti-mycobacterial therapy has poor compliance due to requirement of prolonged treatmen...

متن کامل

New Potential Targets for Fighting against Multi - Drug Resistant Tuberculosis

Tuberculosis has re-emerged as a serious public health threat worldwide because of a significant increase in multiple drug resistant Mycobacterium tuberculosis varieties and a synergy between HIV and M. tuberculosis infection. It has been over 40 years since a new drug for tuberculosis has been discovered. The increasing emergence of drug resistant TB, and HIV infection, which compromises host ...

متن کامل

Mefloquine as a potential drug against multidrug-resistant tuberculosis

Support statement: This work was supported by the State of New Mexico (appropriation from the Tobacco Settlement Fund), from the National Institutes of Health (P50HL107165 for B. Celli and Y. Tesfaigzi, RO1 HL068111 and ES015482 to Y. Tesfaigzi, R01CA164782 for Y. Tesfaigzi/S.A. Belinsky, R01 CA097356 for S.A. Belinsky, HL105339, HL114501, AI111475 for C.A. Owen, FAMRI CIA 123046 for C.A. Owen)...

متن کامل

Mefloquine as a potential drug against multidrug-resistant tuberculosis.

In the article by ALSAAD et al. [1] in a recent issue of the European Respiratory Journal the authors reviewed six drugs with antimicrobial activity against Mycobacterium tuberculosis (phenothiazine, metronidazole, doxycycline, disulfiram, tigecycline and co-trimoxazole) which are not listed in the World Health Organization guidelines on multidrug-resistant tuberculosis (MDR-TB) treatment, but ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: EPRA international journal of research & development

سال: 2022

ISSN: ['2455-7838']

DOI: https://doi.org/10.36713/epra10998